Biocompatibility Evaluation of Modified PEEK: Standards, Testing Items, and Methods for Medical-Grad

Modified polyetheretherketone (PEEK) composites—including carbon fiber reinforced, ceramic filled, and surface functionalized grades—are increasingly used in permanent orthopedic and dental implants, making rigorous biocompatibility evaluation essential for regulatory approval. This article provides a comprehensive technical overview of modified PEEK biocompatibility assessment based on the ISO 10993 series, covering sample preparation, required test endpoints, laboratory methods, and typical application scenarios. Whether you are developing CFR-PEEK spinal implants or bioactive HA-PEEK dental devices, this guide explains how accredited third-party laboratories evaluate the biological safety of these advanced biomaterials.

Technical Overview

Polyetheretherketone (PEEK) is a high-performance, semi-crystalline thermoplastic widely adopted in medical device manufacturing due to its excellent mechanical strength, chemical inertness, radiolucency, compatibility with MRI and CT imaging, and resistance to steam, gamma, and ethylene oxide sterilization. With an elastic modulus of approximately 3.6 GPa, however, neat PEEK is substantially less stiff than cortical bone (10–30 GPa) and is inherently bioinert, which can lead to stress shielding and limited osseointegration in load-bearing applications.

To address these limitations, material developers have introduced a range of modifications: carbon fiber reinforcement (raising the modulus to roughly 18 GPa to match cortical bone), bioactive ceramic fillers such as hydroxyapatite (HA), beta-tricalcium phosphate, and bioactive glass to promote bone ongrowth, and surface engineering techniques including sulfonation, plasma treatment, sandblasting, and hydroxyapatite or titanium coatings. Antimicrobial variants incorporating silver ions or organic agents have also emerged to reduce implant-associated infection risk.

Because every modification alters the chemical composition, surface energy, extractables profile, and potentially the degradation behavior of the base polymer, each modified PEEK formulation must undergo an independent biological safety evaluation. The evaluation follows the risk-based framework of ISO 10993-1, which classifies devices by nature of body contact (surface-contacting, externally communicating, or implant devices) and contact duration (limited, prolonged, or permanent). Most modified PEEK implants, such as spinal fusion cages and bone fixation plates, fall into the permanent-contact bone implant category, which triggers the most comprehensive set of biological endpoints. ASTM F2026, the standard specification for PEEK polymers for surgical implant applications, provides complementary material requirements, and chemical characterization under ISO 10993-18 supports the overall toxicological risk assessment.

Testing Samples

All biological test samples must represent the final commercial formulation, the final manufacturing and post-processing conditions, and the sterilization method, since additives, machining residues, thermal history, and sterilization can all influence test outcomes. The principal modified PEEK sample categories are described below.

Carbon Fiber Reinforced PEEK (CFR-PEEK)

Typically containing 30 wt% short chopped carbon fiber, CFR-PEEK samples must be evaluated for potential release of fiber fragments and surface sizing agents from the fiber reinforcements. Samples are supplied as compression-molded sheets, injection-molded plaques, machined coupons, or representative sections of the finished implant geometry.

Bioactive Ceramic-Filled PEEK

Composites incorporating 5–40 vol% hydroxyapatite, beta-tricalcium phosphate, strontium-substituted apatite, or bioactive glass require careful control of extract pH shifts and ionic release (calcium, phosphate, strontium, silicon), which can otherwise confound in vitro cytotoxicity results.

Surface-Modified PEEK

Sulfonated, plasma-treated, laser-textured, sandblasted, and coated variants must be tested in their final treated state. Residual sulfonic acid groups from sulfonation, for example, must be neutralized and verified before testing. Biological evaluation of these samples is accompanied by surface characterization—SEM morphology, contact angle, FTIR, and XPS—consistent with ISO 10993-19.

Functionally Additized PEEK

Grades containing antimicrobial agents such as silver-loaded zeolites, iodine, or chitosan, as well as drug-eluting formulations, require release kinetics studies in addition to standard biocompatibility endpoints, so that laboratory doses can be justified against clinical exposure.

Testing Items

For permanent-contact implant devices made from modified PEEK, ISO 10993-1 identifies the following biological endpoints, with the final test scope justified through a documented biological evaluation plan and gap analysis of existing data:

• Cytotoxicity (ISO 10993-5)
• Sensitization, delayed-type hypersensitivity (ISO 10993-10)
• Irritation and intracutaneous reactivity (ISO 10993-23)
• Acute, subacute, and subchronic systemic toxicity (ISO 10993-11)
• Genotoxicity (ISO 10993-3)
• Local effects after implantation (ISO 10993-6)
• Hemocompatibility, for blood-contacting applications (ISO 10993-4)
• Carcinogenicity and reproductive toxicity, on a case-by-case rationale basis
• Ethylene oxide residuals, if ETO sterilization is used (ISO 10993-7)
• Material characterization and toxicological risk assessment (ISO 10993-18 and ISO 10993-17)
• Degradation assessment for resorbable fillers or coatings (ISO 10993-13, ISO 10993-14, ISO 10993-15)

Physical and chemical characterization of the polymer itself—including molecular weight, crystallinity, filler dispersion, and thermal properties—provides essential supporting data for the biological evaluation file and is typically performed alongside the biological tests.

Testing Methods

Sample Preparation and Extraction

Extracts are prepared according to ISO 10993-12 using both polar media (physiological saline, serum-supplemented culture medium, or water) and non-polar media (sesame or cottonseed oil). Standard surface-area-to-volume ratios of 3 cm²/mL for formed devices or 0.1–0.2 g/mL for irregular pieces apply. Extraction conditions commonly include 37°C for 72 hours as the nominal condition, or accelerated conditions such as 50°C for 72 hours, 70°C for 24 hours, or 121°C for 2 hours, always selected to remain below conditions that deform the material or alter its chemistry.

Cytotoxicity Testing

The extract dilution (elution) method using L929 mouse fibroblast or V79 cells is the standard approach, with cell viability quantified by MTT or WST-1 colorimetric assays; viability of 70% or greater relative to the blank control indicates a pass. Direct contact and agar overlay methods are useful adjuncts for surface-modified samples where surface effects, not extractables, drive the biological response.

Sensitization and Irritation Testing

Sensitization is evaluated by the guinea pig maximization test or the murine local lymph node assay (LLNA) per ISO 10993-10. Intracutaneous reactivity involves injecting polar and non-polar extracts intracutaneously in rabbits and scoring erythema and edema against the vehicle control in accordance with ISO 10993-23.

Systemic Toxicity Testing

Acute systemic toxicity is assessed in mice following intravenous or intraperitoneal administration of extracts, with 72-hour observation of clinical signs, body weight, and mortality. Subacute (14–28 day) repeated-dose studies are added when the chemical characterization identifies leachables of concern or when novel additives lack an established safety profile.

Genotoxicity Testing

A standard battery per ISO 10993-3 includes the bacterial reverse mutation (Ames) test with and without metabolic activation, an in vitro mammalian chromosomal aberration or mouse lymphoma assay, and an in vivo rodent micronucleus test. Positive findings trigger additional follow-up testing or formulation changes.

Hemocompatibility Testing

For blood-contacting modified PEEK devices, ISO 10993-4 and ASTM F756 testing typically includes the direct contact hemolysis assay using rabbit or human blood (hemolysis ratios below 5% are generally acceptable), complement activation markers such as SC5b-9 and C3a, coagulation assays (PT and APTT), and platelet adhesion and activation assessment by scanning electron microscopy.

Implantation Studies

Local tissue response is evaluated by implanting modified PEEK test rods or coupons into the paravertebral muscle of rabbits alongside a negative control material, per ISO 10993-6. Histopathological examination at 1, 4, 12, and 26 or more weeks scores inflammatory cell response, fibrous capsule thickness, necrosis, and debris, using comparative numerical scoring against the control site.

Chemical Characterization and Risk Assessment

Extractables and leachables are profiled by GC-MS, LC-MS, and ICP-MS, targeting residual monomers and oligomers, solvent residues, fiber sizing agents, catalyst residues, and ionic species released from bioactive fillers. Identified compounds are subjected to toxicological risk assessment with tolerable intake and margin-of-safety calculations under ISO 10993-17, closing the biological evaluation loop defined by ISO 10993-1 and ISO 10993-18.

Applications

Biocompatibility-tested modified PEEK materials serve a growing range of permanent implant applications in which tailored mechanical and biological performance is required:

• Spinal interbody fusion cages and standalone cages in both PEEK and CFR-PEEK grades, where matched bone modulus reduces stress shielding
• Dental implants, abutments, and overdenture components, particularly HA-filled or surface-bioactivated grades
• Cranial reconstruction plates and burr hole covers benefiting from radiolucency and imaging compatibility
• Orthopedic trauma fixation plates, screws, and intramedullary nail systems
• Arthroplasty components such as finger joint spacers and bearing surfaces in CFR-PEEK
• Patient-specific additive-manufactured implants in PEEK-family polymers, including PEKK-based formulations

Documented ISO 10993 biocompatibility evaluation reports issued by accredited third-party laboratories are a core technical dossier component for regulatory submissions, including FDA 510(k) and PMA pathways in the United States, EU MDR conformity assessment through notified bodies, and registrations with authorities in China, Japan, and other major markets.

FAQ

Why does modified PEEK require separate biocompatibility evaluation if medical-grade PEEK is already certified?

Biocompatibility certifications apply to a specific material formulation, manufacturing process, and sterilization method. Any change in fillers, fibers, surface treatment, or additives introduces new extractables and surface characteristics, so the modified grade is treated as a new material requiring its own evaluation, although existing data can be leveraged through a documented gap analysis under ISO 10993-1.

What is the minimum test set for a permanent modified PEEK implant?

Typically, cytotoxicity, sensitization, irritation, genotoxicity, local implantation effects, and comprehensive material characterization form the core package. Hemocompatibility, subchronic toxicity, and degradation studies are added based on the device's blood contact, novel additives, or resorbable components.

How are bioactive fillers handled if they shift the pH of extracts?

Laboratories characterize extract pH and ionic content and may adjust extraction ratios or durations within standard limits. Significant pH deviations are documented and interpreted together with cytotoxicity data to distinguish buffering artifacts from genuine cytotoxic effects.

How long does a complete evaluation take?

In vitro screening tests generally complete within 4 to 8 weeks, while genotoxicity and systemic toxicity studies require 3 to 5 months. Implantation studies with 12-week and 26-week endpoints extend the overall timeline to 6 to 9 months when included.

What sample quantities should be prepared for testing?

As a practical guide, 20 to 40 finished devices or several hundred square centimeters of representative material are sufficient for most in vitro and in vivo programs, with exact quantities defined by the laboratory according to the confirmed test scope and ISO 10993-12 extraction requirements.